Cancer Advisor

OneDayMD Evidence Guide · Cancer & Repurposed Medicines A one-stop review of the laboratory research, human clinical studies, patient stories, commonly discussed protocols, safety concerns and primary references for three antiparasitic medicines that have attracted attention as possible cancer treatments. Updated: 13 October 2026 · Editorial review: OneDayMD Editorial Team · Scope: Evidence appraisal and source navigation, not an individualized treatment plan. Important medical safety note Ivermectin, mebendazole and fenbendazole are not interchangeable, and none is an established treatment for cancer. Ivermectin and mebendazole have approved uses for certain parasitic infections in humans; fenbendazole is a veterinary medicine and is not approved by the US FDA for human use. The American Society of Clinical Oncology (ASCO) advised in June 2026 that ivermectin and fenbendazole should not be used to treat cancer—or as an adjunct to established cancer...

SmartCancer | Evidence Methods Cancer patients and families increasingly encounter reports about medicines originally developed for other conditions that are being investigated or used experimentally for cancer. These reports range from peer-reviewed case studies to laboratory research, social media testimonials and claims of long-term remission. The Repurposed Cancer Drugs: Case Evidence Registry and Outcomes Audit establishes a structured framework for cataloguing these reports, tracing them to their sources, assessing the quality of the available documentation and distinguishing reported outcomes from independently verified clinical responses. Registry status and scope This page defines the registry's proposed methodology, data fields and audit rules. It does not represent a completed systematic review, a fully populated clinical registry or an independently verified collection of patient outcomes. Individual records and aggreg...